Akeso’s Lung Cancer Drug Takes Center Stage at ASCO Plenary: What Survival Data Reveals
Akeso and Summit Therapeutics’ experimental lung cancer drug ivonescimab is the focus of Wall Street speculation ahead of ASCO’s annual meeting. The u...
Xeber.world
oncology
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
How Kelonia Therapeutics’ $3.25B buyout reveals CAR-T’s high-stakes turnaround and drugmakers’ new strategies
Kelonia Therapeutics, a CAR-T biotech on the brink of collapse three times, was acquired by Eli Lilly for $3.25 billion. The deal highlights the secto...
FDA Rejects Promising Melanoma Drug RP1: Doctors Slam Decision as 'Shocking' and Life-Threatening
The FDA has rejected Replimune’s melanoma treatment RP1, a drug doctors say could save lives. Robert F. Kennedy Jr. denies involvement, blaming FDA Co...
Revolution Medicines Unveils Promising KRAS Drug Data and Novel RAS Inhibitor at AACR 2024
Revolution Medicines presented strong clinical trial data for its next-generation KRAS inhibitor, daraxonrasib, in advanced pancreatic cancer at the A...
Revolution Medicines’ KRAS Drug Shows Strong Results at AACR 2024; NCI Director Addresses Funding Concerns
Revolution Medicines’ experimental KRAS drug, daraxonrasib, doubled survival rates in second-line pancreatic cancer patients compared to chemotherapy....
Metformin May Match Exercise Benefits in Prostate Cancer Patients by Boosting 'Exercise Molecule'
A new study reveals that the diabetes drug metformin may mimic a key effect of exercise in prostate cancer patients by increasing levels of an 'exerci...